WO2000053231A3 - Fatty acid-anticancer conjugates and uses thereof - Google Patents

Fatty acid-anticancer conjugates and uses thereof Download PDF

Info

Publication number
WO2000053231A3
WO2000053231A3 PCT/US2000/006160 US0006160W WO0053231A3 WO 2000053231 A3 WO2000053231 A3 WO 2000053231A3 US 0006160 W US0006160 W US 0006160W WO 0053231 A3 WO0053231 A3 WO 0053231A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
conjugates
anticancer
anticancer conjugates
formulations
Prior art date
Application number
PCT/US2000/006160
Other languages
French (fr)
Other versions
WO2000053231A2 (en
Inventor
Nigel L Webb
Matthews O Bradley
Forrest Anthony
Mark Fisher
Original Assignee
Protarga Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/265,307 external-priority patent/US7235583B1/en
Application filed by Protarga Inc filed Critical Protarga Inc
Priority to JP2000603720A priority Critical patent/JP2002538224A/en
Priority to CA2366723A priority patent/CA2366723C/en
Priority to EP00916188A priority patent/EP1163011A2/en
Priority to KR1020017011387A priority patent/KR20020000147A/en
Priority to AU37333/00A priority patent/AU3733300A/en
Publication of WO2000053231A2 publication Critical patent/WO2000053231A2/en
Publication of WO2000053231A3 publication Critical patent/WO2000053231A3/en
Priority to HK02100653.6A priority patent/HK1040486A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates are also provided.
PCT/US2000/006160 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof WO2000053231A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000603720A JP2002538224A (en) 1999-03-09 2000-03-09 Fatty acid-anticancer conjugate and use thereof
CA2366723A CA2366723C (en) 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof
EP00916188A EP1163011A2 (en) 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof
KR1020017011387A KR20020000147A (en) 1999-03-09 2000-03-09 Fatty Acid-Anticancer Conjugates and Uses Thereof
AU37333/00A AU3733300A (en) 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof
HK02100653.6A HK1040486A1 (en) 1999-03-09 2002-01-28 Fatty acid-anticancer conjugates and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/265,307 US7235583B1 (en) 1999-03-09 1999-03-09 Fatty acid-anticancer conjugates and uses thereof
US09/265,307 1999-03-09
US18615200P 2000-03-01 2000-03-01
US60/186,152 2000-03-01

Publications (2)

Publication Number Publication Date
WO2000053231A2 WO2000053231A2 (en) 2000-09-14
WO2000053231A3 true WO2000053231A3 (en) 2001-10-04

Family

ID=26881822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006160 WO2000053231A2 (en) 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof

Country Status (10)

Country Link
EP (1) EP1163011A2 (en)
JP (1) JP2002538224A (en)
KR (1) KR20020000147A (en)
CN (1) CN1377282A (en)
AU (1) AU3733300A (en)
CA (1) CA2366723C (en)
CZ (1) CZ20013123A3 (en)
HK (1) HK1040486A1 (en)
RU (1) RU2001127313A (en)
WO (1) WO2000053231A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US8552054B2 (en) * 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
US7816398B2 (en) * 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
PT1509256E (en) 2002-05-24 2009-10-15 Angiotech Int Ag Compositions and methods for coating medical implants
EP1633380A4 (en) * 2003-06-19 2010-08-11 Yeda Res & Dev Antimicrobial and anticancer lipopeptides
EP1703904B1 (en) * 2003-10-30 2013-02-13 The Research Foundation of the State University of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
EP1862183B1 (en) * 2005-03-14 2010-11-03 Otsuka Pharmaceutical Factory, Inc. Kit comprising drug and fat emulsion
KR100753112B1 (en) * 2007-02-26 2007-08-29 (주)고려다이나믹스 System for issuance of card
US9480752B2 (en) * 2012-07-10 2016-11-01 Baseclick Gmbh Anandamide-modified nucleic acid molecules
WO2023221961A1 (en) * 2022-05-20 2023-11-23 上海维洱生物医药科技有限公司 Triptolide lignocerate, liposome thereof and preparation method therefor
KR20230174082A (en) * 2022-06-20 2023-12-27 (주) 바이오인프라생명과학 Method for manufacturing ultrasound-sensitive carriers for drug delivery and ultrasound-sensitive carriers using the same
CN116676355B (en) * 2023-08-03 2023-10-24 成都第一制药有限公司 Method for catalytic synthesis of anisodamine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011668A1 (en) * 1991-12-10 1993-06-24 Rush-Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
WO1997044063A2 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Dha-pharmaceutical agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
WO1999052887A1 (en) * 1998-04-10 1999-10-21 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925327A (en) * 1982-07-31 1984-02-09 Hidematsu Hirai Preparation of antitumor complex

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011668A1 (en) * 1991-12-10 1993-06-24 Rush-Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
WO1997044063A2 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Dha-pharmaceutical agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6080877A (en) * 1996-05-22 2000-06-27 Neuromedica, Inc. Taxanes
WO1999052887A1 (en) * 1998-04-10 1999-10-21 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same

Also Published As

Publication number Publication date
WO2000053231A2 (en) 2000-09-14
CZ20013123A3 (en) 2002-03-13
HK1040486A1 (en) 2002-06-14
EP1163011A2 (en) 2001-12-19
AU3733300A (en) 2000-09-28
CA2366723C (en) 2011-08-02
CA2366723A1 (en) 2000-09-14
RU2001127313A (en) 2003-09-20
JP2002538224A (en) 2002-11-12
KR20020000147A (en) 2002-01-04
CN1377282A (en) 2002-10-30

Similar Documents

Publication Publication Date Title
WO2002076404A3 (en) Fatty alcohol drug conjugates
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
CA2255615A1 (en) Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
DE69716135D1 (en) In 6-position durch thio substituierte paclitaxele
CA2310850A1 (en) A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2001285143A1 (en) Methods and compositions for targeted delivery
HUP0202762A3 (en) Solid lipid compositions, process for their preparation and use thereof
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
WO2000066528A3 (en) Quinones for treatment of diseases
EP0895777A3 (en) Compositions based on peroxyacids
IL206604A (en) Transmembrane protein, 24p4c12, expressed in prostate cancer, immunogenic compositions comprising them and uses thereof
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
WO2003053365A3 (en) Syn3 compositions and methods
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002024179A3 (en) Method for reducing toxicity of combined chemotherapies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804762.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/864/KOL

Country of ref document: IN

Ref document number: 37333/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2001-3123

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2366723

Country of ref document: CA

Ref document number: 2366723

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017011387

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 603720

Country of ref document: JP

Kind code of ref document: A

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000916188

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000916188

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017011387

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-3123

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-3123

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017011387

Country of ref document: KR